• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clinical Trials

GlucoModicum has positive data for needle-free CGM

July 2, 2025 By Sean Whooley

GlucoModicum needle-free CGM (1)

GlucoModicum today announced positive outcomes from a clinical performance study of its needle-free continuous glucose monitor (CGM). Helsinki, Finland-based GlucoModicum said in a news release that the study helps put the company on “a clear path to commercialization.” The study involved 646 participant visits, including individuals with type 2 diabetes and healthy volunteers. The company […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: GlucoModicum

Glucotrack first-in-human study of long-term CBGM implant meets endpoints

June 25, 2025 By Sean Whooley

Glucotrack 3-year continuous blood glucose monitor (CBGM)

Glucotrack (Nasdaq:GCTK) today announced the results from the first-in-human clinical study of its long-term continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack shared findings at the American Diabetes Association’s 85th Scientific Sessions in Chicago. (See all the biggest stories out of ADA 2025 here.) Glucotrack’s device features no on-body external component. The company designed […]

Filed Under: Clinical Trials, Diabetes, Implants, Patient Monitoring, Technology Tagged With: ADA 2025, Glucotrack

The biggest diabetes tech stories out of ADA 2025

June 24, 2025 By Sean Whooley

ADA Logo in Chicago American Diabetes Association 85th Scientific Sessions

The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, ADA 2025, Beta Bionics, biolinq, Dexcom, Eli Lilly & Co., Glucotrack, Insulet, LifePlus, mannkind, Medtronic, minimed, modularmedical, PharmaSens, Senseonics, Sequel Med Tech, SiBionics, Tandem Diabetes Care, Vaxess Technologies

Mannkind looks to give those with diabetes another option through inhaled insulin

June 24, 2025 By Sean Whooley

MannKind afrezza inhaled insulin in use

For those living with diabetes, MannKind offers a very different alternative to the current methods of insulin delivery. Founded in 1991 by Alfred E. Mann, a medtech visionary who played a large part in the wider adoption of insulin pumps as the founder of MiniMed, the company develops Afrezza — a fast-acting insulin formulation delivered […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: ADA 2025, mannkind

Modular Medical study shows potential benefits of pump-delivered GLP-1s

June 24, 2025 By Sean Whooley

Modular Medical modd1 insulin pump

Modular Medical (Nasdaq:MODD) has shared new data highlighting the use of its insulin pump technology to deliver GLP-1 therapeutics. The company shared its findings in a poster presentation at the American Diabetes Association’s 85th Scientific Sessions in Chicago. San Diego-based Modular Medical develops the MODD1 product, a 90-day patch pump. It features new microfluidics technology […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Technology Tagged With: ADA 2025, modularmedical

Omnipod 5 rollout for type 2 advances as Insulet pursues next-gen automation

June 23, 2025 By Sean Whooley

Insulet Omnipod 5 with Dexcom G7

When it comes to the diabetes tech market, the Insulet (Nasdaq:PODD) Omnipod 5 automated insulin delivery system is nothing new. Omnipod 5 first received FDA clearance for individuals aged 6 years old and up with type 1 diabetes in January 2022. At that point, it became the world’s first available tubeless, wearable, automated insulin delivery […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: ADA 2025, Insulet

LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor

June 23, 2025 By Sean Whooley

LifePlus LifeLeaf non-invasive continuous glucose monitor_blood pressure monitor CGM

LifePlus today announced the clinical validation of its LifeLeaf non-invasive and cuffless wearable for continuous glucose and blood pressure tracking. The device delivers real-time insights without needles, invasive sensors or cuffs. Global, multi-center trials conducted across the Mayo Clinic, AMCR Clinic – San Diego Cleveland Clinic – Abu Dhabi, and Hospital Sebarang Jaya – Penang, […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Patient Monitoring, Technology Tagged With: ADA 2025, LifePlus

Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

June 23, 2025 By Sean Whooley

Biolinq intradermal glucose sensor

A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy. Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino acid. Released from […]

Filed Under: Clinical Trials, Diabetes, Featured, Implants, Patient Monitoring, Technology Tagged With: ADA 2025, biolinq

Vaxess study highlights GLP-1 delivery with microarray patch

June 23, 2025 By Sean Whooley

Vaxess Technologies MIMIX vaccine patch

Vaxess Technologies today shared new preclinical data highlighting the capability of its drug delivery patch to deliver semaglutide. Semaglutide, a GLP-1 receptor agonist, is currently a treatment option for both diabetes and obesity management. Woburn, Massachusetts-based develops a microarray patch (MAP) designed to deliver drugs.  It features a soluble microarray with tips that gradually dissolve […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Pharmaceuticals, Technology Tagged With: ADA 2025, Vaxess Technologies

Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results

June 22, 2025 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: ADA 2025, Eli Lilly, Eli Lilly & Co.

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 103
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS